- Home
- PRZO vs MBRX Comparison
PRZO vs MBRX Comparison
Compare PRZO & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRZO
- MBRX
- Stock Information
- Founded
- PRZO 2014
- MBRX 2015
- Country
- PRZO Israel
- MBRX United States
- Employees
- PRZO N/A
- MBRX N/A
- Industry
- PRZO
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- PRZO
- MBRX Health Care
- Exchange
- PRZO Nasdaq
- MBRX Nasdaq
- Market Cap
- PRZO 14.8M
- MBRX 12.9M
- IPO Year
- PRZO 2023
- MBRX 2016
- Fundamental
- Price
- PRZO $1.29
- MBRX $0.27
- Analyst Decision
- PRZO
- MBRX Strong Buy
- Analyst Count
- PRZO 0
- MBRX 3
- Target Price
- PRZO N/A
- MBRX $5.33
- AVG Volume (30 Days)
- PRZO 1.5M
- MBRX 1.8M
- Earning Date
- PRZO 03-21-2025
- MBRX 08-13-2025
- Dividend Yield
- PRZO N/A
- MBRX N/A
- EPS Growth
- PRZO N/A
- MBRX N/A
- EPS
- PRZO N/A
- MBRX N/A
- Revenue
- PRZO $932,154.00
- MBRX N/A
- Revenue This Year
- PRZO N/A
- MBRX N/A
- Revenue Next Year
- PRZO N/A
- MBRX N/A
- P/E Ratio
- PRZO N/A
- MBRX N/A
- Revenue Growth
- PRZO 50.22
- MBRX N/A
- 52 Week Low
- PRZO $0.49
- MBRX $0.25
- 52 Week High
- PRZO $3.16
- MBRX $4.71
- Technical
- Relative Strength Index (RSI)
- PRZO 63.22
- MBRX 17.81
- Support Level
- PRZO $1.10
- MBRX $0.63
- Resistance Level
- PRZO $1.40
- MBRX $0.73
- Average True Range (ATR)
- PRZO 0.10
- MBRX 0.08
- MACD
- PRZO 0.01
- MBRX -0.03
- Stochastic Oscillator
- PRZO 79.40
- MBRX 2.49
About PRZO ParaZero Technologies Ltd.
ParaZero Technologies Ltd is an aerospace company that is focused on drone safety systems and engaged in the business of designing, developing, and providing autonomous parachute safety systems for commercial drones, also known as unmanned aerial systems. The ParaZero SafeAir system of the company applies real-time data analytics to identify and mitigate flight risks autonomously and increase safety for bystanders while protecting the loss of expensive drones, equipment, and payloads.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.